On March 26, Ge Longhui (06667.HK) announced that for the year ended December 31, 2023, the company achieved revenue of RMB 151.3 million, an increase of 3.8% over the previous year; without considering the impact of COVID-19 testing services, revenue increased 16.8% year on year. Net profit was RMB 30.0 million, and the loss for the same period in 2022 was RMB 17.6 million. Net profit increased by RMB 47.6 million compared to 2022; mainly due to the company implementing a more active market strategy during the reporting period, speeding up sales channel expansion, enriching the product matrix, continuously optimizing the product structure of genetic testing services, and increasing cost control and collection of accounts receivable, net profit increased dramatically.
美因基因(06667.HK)年度实现营业收入1.51亿元 同比增长3.8%
MineGene (06667.HK) achieved annual revenue of 151 million yuan, an increase of 3.8% year-on-year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.